Adrenna Jackson, NP
Primary Care · Columbia, SCNPI 1912644246
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Dexcom, Inc. at 24.9% of the total. Reporting peaked in 2024 at $1,012 and has fallen 72.0% since, to $283 in 2025.
Across 95 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$493
- Lilly USA, LLC$276
- AbbVie$217
- Exact Sciences$179
- Otsuka America Pharmaceutical, Inc.$149
- AstraZeneca$111
- plus $554 from 17 others
What the payments were for
- Food & beverage$1,979100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 13 | $493 |
| Lilly USA, LLC | 18 | $276 |
| AbbVie | 16 | $217 |
| Exact Sciences | 10 | $179 |
| Otsuka America Pharmaceutical, Inc. | 2 | $149 |
| AstraZeneca | 7 | $111 |
| Amgen | 4 | $104 |
| Novo Nordisk | 5 | $96 |
| Xeris Pharmaceuticals, Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Inari Medical, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Hospira, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Pfizer | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$122
How this compares
$1,979 in reported general payments places this provider in the 70th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 23 | $34,814 |
| JardianceEmpagliflozin | 13 | $18,438 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $826 |
| Fluticasone Propionate | 34 | $491 |
| Rosuvastatin Calcium | 44 | $354 |
| Metformin Hcl ErMetformin Hcl | 25 | $335 |
| Atorvastatin Calcium | 57 | $309 |
| Gabapentin | 25 | $297 |
| Omeprazole | 16 | $247 |
| Amlodipine Besylate | 52 | $209 |
| Nystatin | 14 | $190 |
| Tramadol Hcl | 12 | $171 |
| Triamcinolone Acetonide | 28 | $163 |
| Ezetimibe | 12 | $151 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 14 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $276 | $34,81423 claims |
| Boehringer IngelheimJardiance | $47 | $18,43813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 115 primary care providers in South Carolina.
Other primary care in Columbia
- Patricia HeadColumbia$6K
- Lyndsey MathiasColumbia$3K
- Yolanda Boyd-GanttColumbia$3K
- Madeline SmithColumbia$2K
- Jennifer GillisColumbia$2K
- Marisa GentryColumbia$2K
- Hadyn GauseColumbia$2K
- Mollie CottyColumbia$2K
- Deidra WillisColumbia$1K
- Tiffany JohnsonColumbia$787
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.